Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study

BACKGROUND: ‘Long COVID’ describes persistent symptoms, commonly fatigue, lasting beyond 12 weeks following SARS-CoV-2 infection. Potential causes include reduced mitochondrial function and cellular bioenergetics. AXA1125 has previously increased β-oxidation and improved bioenergetics in preclinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Finnigan, Lucy E.M., Cassar, Mark Philip, Koziel, Margaret James, Pradines, Joel, Lamlum, Hanan, Azer, Karim, Kirby, Dan, Montgomery, Hugh, Neubauer, Stefan, Valkovič, Ladislav, Raman, Betty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102537/
https://www.ncbi.nlm.nih.gov/pubmed/37223439
http://dx.doi.org/10.1016/j.eclinm.2023.101946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102537/
https://www.ncbi.nlm.nih.gov/pubmed/37223439
http://dx.doi.org/10.1016/j.eclinm.2023.101946

Ejemplares similares